The Controversy Concerning Plasma Homocysteine in Parkinson’s Disease Patients Treated with Levodopa alone or with Entacapone: Effects of Vitamin StatusClinical Neuropharmacology (2006)
Levodopa treatment of Parkinson disease results in hyperhomocysteinemia (HHcy) as a consequence of levodopa methylation by catechol-O-methyltransferase (COMT). Although inhibition of COMT should theoretically prevent or reduce levodopa-induced HHcy, results from several prospective studies are conflicting. Our review of these studies suggests that the ability of COMT inhibition to reduce or prevent levodopa-induced HHcy in Parkinson disease patients may be attributed to differences in the vitamin status of the study participants. In patients with low or low-normal folate levels, levodopa administration is associated with a greater increase in homocysteine and concomitant entacapone administration is associated with a greater reduction in homocysteine.
- Plasma Homocysteine,
- Parkinson Disease,
- Vitamin Status
Publication DateMay 29, 2006
Citation InformationKelly L. Sullivan, Theresa A. Zesiewicz, Lynn Wecker, Robert A. Hauser, et al.. "The Controversy Concerning Plasma Homocysteine in Parkinson’s Disease Patients Treated with Levodopa alone or with Entacapone: Effects of Vitamin Status" Clinical Neuropharmacology Vol. 29 Iss. 3 (2006) p. 106 - 111 ISSN: 1537-162X
Available at: http://works.bepress.com/kelly_sullivan/124/